Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02121067 · ClinicalTrials.gov registry record · Phase 4
LNG-IUS at 2 Weeks Postpartum
A Phase 4 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT02121067 is a Phase 4 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 50 participants.
The verdict
NCT02121067, a Phase 4 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a study of 50 postpartum women interested in having the Mirena® LNG-IUS placed for contraception. The Mirena® is an FDA approved intrauterine contraceptive device that provides contraception for 5 years with excellent effectiveness. Women enrolled in this study will only have the Mirena® placed at two-weeks postpartum (day 14-20 postpartum). The participants will be followed at 6-weeks and 6-months postpartum for study visits to evaluate for satisfaction, symptoms, expulsion, and perforation. The study will be completed at six-months postpartum, and participants will be able to keep their LNG-IUS following study completion.
Interventions
- DRUG Levonorgestrel Intrauterine System (LNG-IUS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02121067
The ClinicalTrials.gov registry entry for NCT02121067 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Levonorgestrel Intrauterine System (LNG-IUS) is the first listed.
NCT02121067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02121067 about?
NCT02121067 is a clinical study titled "LNG-IUS at 2 Weeks Postpartum". This is a study of 50 postpartum women interested in having the Mirena® LNG-IUS placed for contraception. The Mirena® is an FDA approved intrauterine contraceptive device that provides contraception for 5 years with excellent effectiveness. Women enrolled in this study will only have the Mirena® pla...
What is the current status of trial NCT02121067?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2014-09. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02121067?
The interventions under investigation include: Levonorgestrel Intrauterine System (LNG-IUS) (DRUG).
Who is sponsoring clinical trial NCT02121067?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.